CAMPYLOBACTER

弯曲杆菌是世界范围内最常见的腹泻原因之一。人类 牛奶通过几种途径保护婴儿免受弯曲杆菌腹泻 包括岩藻糖基化低聚糖的因子。然而，缺乏 了解这些成分的化学结构， 与弯曲杆菌毒力性状相关的相互作用机制 附着在肠粘膜上。该项目的具体目标是：1） 确定与附着相关的弯曲杆菌毒力标记 上皮细胞; 2）表征和纯化乳糖缀合物， 抑制弯曲杆菌感染; 3）评估乳房被动保护- 喂养儿童并在携带人类的转基因小鼠中进行实验 岩藻糖基转移酶基因主要在乳腺组织中表达; 4）发育 岩藻糖基化糖缀合物活性的大规模合成策略 对弯曲杆菌感染;和5）进行安全性的临床试验 和岩藻糖基化糖缀合物抗弯曲杆菌的保护作用 腹泻该项目的长期目标是开发方法， 通过了解弯曲杆菌感染的预防和治疗 在细胞和分子水平上， 母乳对弯曲杆菌感染。

Campylobacter is one of the most common cause of diarrhea worldwide. Human milk protects young infants against Campylobacter diarrhea by several factors including fucosylated oligosaccharides. However, there is a lack of understanding of the chemical structure of these components and their mechanism of interaction with Campylobacter virulence traits associated with attachment to gut mucosa. The specific aims of this project are: 1) define the virulence markers of Campylobacter associated with attachment to epithelial cells; 2) characterize and purify milk glycoconjugates that inhibit Campylobacter infection; 3) assess passive protection in breast- fed children and experimentally in transgenic mice carrying a human fucoslytransferase gene expressed mainly in mammary tissue; 4) develop strategies for large-scale synthesis of fucosylated glycoconjugates active against Campylobacter infection; and 5) conduct clinical trials on safety and protection of fucosylated glycoconjugates against Campylobacter diarrhea. The long-term goal of this project is to develop methods for prevention and treatment of Campylobacter infection through understanding at the cellular and molecular level the mechanism of protection conferred by human milk against Campylobacter infection.